Home > Oncology > ESMO 2021 > Genitourinary Cancer > Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Presented By
Prof. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy
Conference
ESMO 2021
Trial
Phase 3, KEYNOTE-826
First results from KEYNOTE-826 showed that addition of pembrolizumab to chemotherapy ± bevacizumab significantly improved survival in patients with persistent, recurrent, or metastatic cervical cancer, regardless of PD-L1 expression. Standard treatment for persistent, recurrent, or metastatic cervical cancer is platinum-based chemotherapy, with platinum, paclitaxel, and bevacizumab as a preferred regimen [1]. PD-L1 inhibitors have shown efficacy as monotherapy in previously treated patients with cervical cancer [2,3]. KEYNOTE-826 (NCT03635567) evaluated the efficacy and safety of pembrolizumab plus chemotherapy (plus bevacizumab at the investigators’ and patients’ discretion). Eligible patients had persistent, recurrent, or metastatic cervical cancer, were not amenable to curative treatment, and had not previously been treated with systemic chemotherapy (unl...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on